Recombinant SARS-CoV-2 vaccine, NDV vector (Wanbangde)

重组新城疫病毒载体新冠疫苗（万邦德）

Report date: 2022/04/19 10:32:19

Base Information

Drug NameRecombinant SARS-CoV-2 vaccine, NDV vector (Wanbangde)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversal Pharmaceutical Group Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesUniversal Pharmaceutical Group Co Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A